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Relation between serum sodium levels and clinical outcomes in 
Turkish patients hospitalized for heart failure: a multi-center 
retrospective observational study
Introduction
Hyponatremia is a frequent finding in patients hospitalized for 
heart failure (HF), with a prevalence of 8%–28% (1–7). Besides 
being frequent, it also has been established as a poor prognostic 
factor for both out- and inpatients with HF (2–13). It is associated 
with both short- and long-term adverse outcomes, including all-
cause death. This adverse effect is not only for those patients 
with reduced EF but also for those with HF and preserved EF (5, 
10). Most of North American, European, and some Asian coun-
tries reported their relevant data for hyponatremia and its impact 
on clinical outcomes in patients with HF. Data on the prevalence 
of hyponatremia and its relation with clinical outcomes in Turk-
ish patients with HF does not exist.
Therefore, in this study, we examined the prevalence of hy-
ponatremia and related 1-year clinical outcomes (mortality and 
rehospitalization) in patients hospitalized for decompensated HF 
with reduced EF. Since relevant data is scarce, we also evaluated 
the association of changes in serum sodium (sNa) at discharge 
with 1-year mortality. This study is expected to fill the above-
Objective: The purpose of the study was to analyze the prevalence of hyponatremia and related 1-year outcomes of patients hospitalized for 
decompensated heart failure with reduced ejection fraction (HFrEF) in Turkish patients.
Methods: A total of 500 hospitalized patients with HFrEF were consecutively included in a retrospective study at 19 participating hospitals. Pa-
tients were categorized according to their serum sodium levels (sNa) on admission day as normonatremic (135–145 mEq/L) and hyponatremic 
(<135 mEq/L). One-year all-cause mortality, re-hospitalization rates, and the impact of the changes in sNa at the time of discharge to clinical 
outcomes were examined.
Results: Hyponatremia was observed in 29% of patients. Patients with hyponatremia had lower blood pressures, creatinine clearance, and left 
ventricular ejection fraction and higher serum creatinine and BUN levels on admission compared with those with normonatremia. Hyponatre-
mia was associated with higher 1-year all-cause mortality (14% vs. 2.6%, p<0.001) and re-hospitalization rates (46.9% vs. 33.7%, p=0.005). After 
adjustment for covariates, hyponatremia was independently associated with 1-year all-cause mortality (adjusted HR, 4.762; 95% CI, 1.941–11.764; 
p=0.001). At discharge, only 50.8% of hyponatremic patients were corrected to normonatremia (≥135 mEq/L). Those with persistent hyponatremia 
had the highest all-cause mortality (p<0.001).
Conclusion: In this study, it is demonstrated that hyponatremia is relatively common and is associated with increased 1-year all-cause mortality 
and re-hospitalization rates among Turkish patients hospitalized with HFrEF. Approximately 50% of the patients with initial low sNa had persistent 
hyponatremia at discharge, and these patients had the worst clinical outcomes. (Anatol J Cardiol 2017; 17: 2-7)
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mentioned gap related with hyponatremia and gain insight into 
clinical outcomes of Turkish patients hospitalized for HF.
Methods
We performed a retrospective chart review study among pa-
tients who were hospitalized because of worsening HF in 19 ter-
tiary care cardiology clinics in Turkey. Adult patients (>18 years 
of age) were eligible to take part in the study if they had signs 
and symptoms of HF, were hospitalized for the treatment of wors-
ening HF before April 2012, and had a left ventricular EF <45% 
as seen on echocardiogram at the time of hospital admission. 
The first 500 charts across the study hospitals were selected ac-
cording to the index hospitalization admission date. There were 
no additional exclusion criteria. Patients were identified using 
the International Classification of Disease: ninth Revision Codes 
from the hospital database.
All variables, including patient history and detailed in-hos-
pital drug history, were obtained from the patient treatment re-
cords and entered into the electronic case report forms (CRFs). 
Laboratory data, including sNa, potassium, creatinine, and BUN 
levels, were recorded on admission. Renal function [creatinine 
clearance (CrCl)] was calculated using the Cockroft–Gault for-
mula. The discharge sNa (defined as the last sNa within 48 h be-
fore discharge) was also recorded in CRF. Missing information 
was noted as unknown. This study complied with the Declara-
tion of Helsinki. The study protocol was approved by the Institu-
tional Ethics Committee of the coordinating center.
Out of 500 patients, a total of 487 patients’ data were included 
in the analysis. Thirteen patients were excluded due to missing 
sNa values at the time of index admission. Hyponatremia was 
defined as sNa concentration <135 mEq/L. The patients were di-
vided into two groups: hyponatremia (sNa<135 mEq/L) and nor-
monatremia (sNa 135–145 mEq/L).
The primary objectives of this study were to compare 1-year 
all-cause mortality and re-hospitalization rates following index 
hospitalization for HF between patients with initial hyponatremia 
and normonatremia. All-cause mortality and re-hospitalization 
data at the follow up were extracted from patient treatment files 
or obtained from a family member or government agency by a 
phone call. In the absence of documented death, patients were 
presumed to be alive at the time of analysis. Further elucidation 
of cause of death was not performed because of the inability to 
obtain complete records from all patients.
Secondary objectives included clinical characteristics, 
the length of index hospitalization, and whether changes in 
sNa levels at the time of discharge affect clinical outcomes. 
To analyze the last secondary objective, the patients were fur-
ther separated into four groups according to their sNa levels 
on admission and at discharge as corrected hyponatremia (ini-
tial sNa<135 mEq/L that increased to ≥135 mEq/L at discharge); 
persistent hyponatremia (sNa<135 mEq/L both at admis-
sion and discharge); hospital-acquired hyponatremia (initial 
sNa≥135 mEq/L that decreased <135 mEq/L at discharge); and 
normonatremia (sNa≥135 both at admission and discharge). Of 
the 483 patients included in the analysis, 416 patients’ (86%) 
admission and discharge sNa values were entered in CRFs. 
One-year all-cause mortality and re-hospitalization were de-
termined in these patients.
Statistics
Statistical analyses were performed in accordance with the 
International Conference of Harmonization (ICH) E9 guidelines 
(14). Admission sNa values were categorized into two discrete 
groups: low sNa (Na<135 mmol/L) and normal sNa (Na≥135 
mmol/L). Based on the EuroHeart Failure Survey study, the 
1-year mortality rate among hospitalized HF patients was 29.5% 
and 18.9% for patients with low sodium levels (Na<135 mmol/L) 
and normal sodium level (Na≥135 mmol/L), respectively. Sample 
size per region of 500 patients allowed for detecting a significant 
difference in 1-year mortality rates between the low and normal 
sNa groups at a power of 0.80 and a two-sided alpha level of 
0.05 (15). Patient characteristics and treatments were compared 
using the chi-square test for categorical variables and Mann–
Whitney U test for continuous variables not normally distributed. 
The relation between sNa concentration and long-term out-
comes was evaluated among patients with the post-discharge 
Cox-proportional hazards model. Kaplan–Meier survival curves 
were constructed to illustrate mortality. The long-rank test was 
used to assess differences between groups. Potential confound-
ers were identified from patient comparisons conducted across 
predefined groups. Results were presented as hazard ratios with 
95% confidence intervals. All data were analyzed using SPSS 21 
software (SPSS Inc., Chicago, IL, USA). Values of p <0.05 were 
considered to be statistically significant.
Results
The clinical characteristics of all patients and patients clas-
sified into two groups, hyponatremia and normonatremia, are 
shown in Table 1. Patients had a median age 65 years and were 
mostly men (70%). The majority of patients (61.4%) had coronary 
artery disease as the etiology of HF.
The frequency of hyponatremia on hospital admission was 
29%. As expected, sNa was lower in patients with hyponatre-
mia (132 mEq/L vs. 139 mEq/L, respectively, p<0.001). Age, gen-
der, diabetes, and smoking history were comparable between 
the two groups. Patients with hyponatremia were more likely 
to have more severe symptoms [New York Heart Association 
(NYHA) Functional Class IV; 30.8% vs. 20.1%, p<0.001] and low-
er blood pressure (BP) (p=0.003 for systolic BP and p=0.001 for 
diastolic BP) on admission. In hyponatremic patients, serum 
creatinine and BUN levels were significantly higher (p=0.001 
and p<0.001, respectively) and CrCl and left ventricle EF were 
significantly lower (p=0.018 and p=0.002) than patients with 
normonatremia.
3
In-hospital medications were compared between the two 
groups (Table 2). The use of angiotensin converting enzyme inhibi-
tors, angiotensin receptor blockers, and beta-blockers were similar. 
The use of intravenous diuretics, inotropic drugs (dopamine and do-
butamine), and spiranolactone were more common in patients with 
hyponatremia (p=0.004, p=0.001, p=0.022 and p=0.036, respectively).
According to admission and discharge sNa levels, 61 (14.7%) 
patients had corrected hyponatremia, 59 (14.2%) patients had per-
sistent hyponatremia, 77 (18.5%) patients had hospital-acquired 
hyponatremia, and 219 (52.6%) patients had normonatremia.
Outcomes
The median duration of follow-up was 330 days. Overall, 29 
patients (6%) died during the follow-up period. Hyponatremia 
was associated with higher 1-year mortality compared with pa-
tients without hyponatremia (14% vs. 2.6% respectively, p<0.001). 
Kaplan–Meier survival curves for the patients with hyponatremia 
and normonatremia are shown in Figure 1. The length of hospi-
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Table 1. Patient characteristics
   Total Hyponatremia Normonatremia P 
   n=487 n=143 n=344
Age, years 65 (18–92) 64 (18–92) 66 (23–91) 0.594
Men, % 341 (70.0) 99 (69.2) 242 (70.3) 0.974
BMI, kg/m2* 28.6±4.5 28.1±4.0 28.8±4.7 0.421
Diabetes mellitus 65 (13.3) 25 (17.5) 40 (11.6) 0.107
Smoking history
 Smoker 44 (9.0) 16 (11.2) 28 (8.1)
 Ex-smoker 87 (17.9) 20 (14.0) 67 (19.5) 
0.326
 Non-smoker 114 (23.4) 30 (21.0) 84 (24.4)
 Unknown 236 (48.5) 76 (53.1) 160 (46.5)
Heart failure etiology
 Ischemic 299 (61.4) 88 (61.5) 211 (61.3)
 Non-ischemic 151 (31.0) 39 (27.3) 112 (32.6) 0.114
 Unknown 37 (7.6) 16 (11.2) 21 (6.1)
NYHA class
 I  7 (1.4) 1 (0.7) 6 (1.7) 
 II  90 (18.5) 25 (17.5) 65 (18.9)
 III  237 (48.7) 66 (46.2) 171 (49.7) 0.108
 IV  113 (23.2) 44 (30.8) 69 (20.1)
 Unknown 37 (7.6) 5 (3.5) 32 (9.3)
LV EF, % 30 (10–44) 27 (10–44) 30.0 (10–44) 0.002
SBP, mm Hg 120 (80–230) 114 (80–160) 120 (80–230) 0.003
DBP, mm Hg 73 (40–120) 70 (40–92) 80 (40–120) 0.001
SBP, ≤100 mm Hg 53 (10.9) 22 (15.4) 31 (9.0) 0.054
SBP, ≥140 mm Hg  75 (15.4) 13 (9.1) 62 (18.0) 0.006
Heart rate, bpm 82 (40–152) 84 (60–146) 82 (40–152) 0.165
Sodiu, mEq/L 138 (111–145) 132 (111–134) 139 (135 -145) <0.001
Potasium, mEq/L 4.5±0.7 4.5±0.9 4.4±0.6 0.259
Creatinine, mg/dL 1.1 (0.9–7) 1.22 (0.9–6) 1.10 (0.9–7) 0.001
Creatinine, 118 (24.2) 48 (33.6) 70 (20.3) 0.003 
>1.5, mg/dL
BUN, mg/dL 26 (7–144) 35 (10–144) 25 (7–128) <0.001
CrCI, mL/min 66.4 (10–230) 54.7 (10–226) 68.7 (22–230) 0.018
BMI - body mass index; BUN - blood urea nitrogen; CrCl - creatinine clearance; DBP 
- diastolic blood pressure; LVEF - left ventricle ejection fraction; SBP - systolic blood 
pressure. *The “±” values are means+SD. Results presented as median, minimum, and 
maximum values for continuous variables with not-normally distributed and numbers 
(percentages) for categorical variables. They were compared using the chi-square 
test for categorical variables and Mann–Whitney U test for continuous variables not-
normally distributed
Table 2. In-hospital management according to presence or absence of 
hyponatremia
   Total Hyponatremia Normonatremia P 
   n=487 n=143 n=344 
   (%) (%) (%)
ACE inhibitors 46.8 51.7 44.8 0.164
ARBs 10.7 9.1 11.3 0.522
Beta blockers 56.7 61.5 54.7 0.192
Antiarrhythmics 7.6 7.7 7.6 0.546
Digitalis 20.5 23.1 19.5 0.390
IV furosemide 46.4 56.6 42.2 0.004
HCTZ 18.3 23.1 16.3 0.094
Spiranolactone 24.2 30.8 21.5 0.036
Dopamine 15.0 23.8 11.3 0.001
Dobutamine 5.1 9.1 3.5 0.022
Levosimendan 4.3 4.2 4.4 0.577
Insulin 10.5 15.4 8.4 0.033
ASA 60.8 65.7 58.7 0.155
Warfarin 14.2 14.7 14.0 0.887
ACE - angiotensin converting enzyme; ARB - angiotensin receptor blocker; ASA - 
asetilsalyclic acid; HCTZ - hydrochlorothiazide; IV - intravenous. Values are given as 
percentages. The chi-square test was used
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Figure 1. Kaplan–Meier survival curves for patients with hyponatremia 
and without hyponatremia
Hyponatremia
Normonatremia
Sodium group
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tal stay was significantly longer in patients with hyponatremia 
(12.8±24.9 days vs. 9.3±24.7 days, p=0.017). The rehospitalization 
rate because of HF was 46.9% in patients with hyponatremia and 
33.7% in those with normonatremia (p=0.005).
The predictors of mortality in the whole group were hypo-
natremia [hazard ratio (HR) 5.38; 95% confidence interval (CI), 
2.45–11.8, p<0.001] and left ventricle EF [HR 1.075; 95% CI, 1.02–
1.13, p=0.006].
In a logistic regression model using normonatremic patients 
as the reference, hyponatremia was significantly associated 
with 1-year all-cause mortality unadjusted HR 6.71; 95% CI, 2.96–
15.15; p<0.001. Hyponatremia was independently associated with 
1-year all-cause mortality adjusted HR 4.762; 95% CI, 1.94–11.76; 
p=0.001 even after adjusting for left ventricle EF, systolic BP, and 
serum creatinine.
Results of 1-year all-cause mortality stratified by groups ac-
cording to the change in sNa levels at discharge are presented 
in Table 3. Patients with normonatremia had the lowest 1-year 
all-cause mortality, whereas those with persistent hyponatremia 
had the highest (2.5% vs. 20%, p<0.001). All-cause mortality rates 
between persistent hyponatremia vs. hospital-acquired hypona-
tremia and corrected hyponatremia vs. normonatremia groups 
were significantly different (p=0.014 and p=0.012, respectively). 
Kaplan–Meier survival curves for the four groups are shown in 
Figure 2. Similarly, rehospitalization rate was highest in the per-
sistent hyponatremia group and lowest in the normonatremia 
group (49.2% vs. 29.2%, p=0.005). Patients with corrected hypo-
natremia at discharge had lower mortality and rehospitalization 
rates than patients with persistent hyponatremia (11.3% vs. 20% 
for mortality and 37.7% vs. 49.2% for rehospitalization), though 
this did not reach statistical significance.
Discussion 
The results of this retrospective observational study per-
formed in Turkish patients corroborate with previous findings 
from various countries, showing that patients with HF and hy-
ponatremia have increased mortality and rehospitalization rates 
compared with normonatremic patients (2, 5, 12, 16). Hence, it can 
be said that the poor prognostic impact of hyponatremia on clini-
cal outcomes in HF is conserved in Turkish patients. The patients 
with hyponatremia have worse left ventricular systolic function 
and lower kidney function. Additionally while the patients with 
persistent hyponatremia have the worst clinical outcomes, in-
hospital correction of hyponatremia on admission may improve 
rehospitalization and mortality rates. Similar to other studies (2, 6, 
16, 17), patients with hyponatremia had prolonged hospital stays, 
which will likely increase the economic burden of the disease.
In this study, we found that the indicators of more severe HF, 
such as lower EF, lower BP, and impaired renal function were 
more common in patients with hyponatremia. Although the rela-
tion between lower left ventricular EF and hyponatremia was not 
significant in some studies (2, 12), the findings of others support 
the significant relation (13, 18) as this study demonstrates. Lower 
systolic BP, another indicator of poor prognosis in HF, was more 
prevalent in hyponatremic patients. When related literature was 
reviewed, this appears to be an almost unanimous finding (5, 6, 
10, 12, 13, 17). Unsurprisingly, this increased the need for intrave-
nous inotropes, which was shown in other studies as well. The 
levels of serum creatinine, BUN, and CrCl indicate worse renal 
function in hyponatremic patients in our study cohort. Similarly, 
serum creatinine levels were found to be higher in most of the 
previous studies (6, 12, 17, 18).
Hyponatremic patients stayed in the hospital for a longer 
time than patients with normal sNa levels. Other studies com-
paring length of hospital stay between hypo- and normona-
tremic patients have reported similar findings (2, 4, 6, 19). Neither 
previous studies nor our study have analyzed the independent 
impact of sNa levels on the length of hospital stay; however, 
it is possible that this is, in part, due to more advanced stages 
of HF observed in hyponatremic patients. Longer hospital stays 
are expected to increase the economic burden of the disease 
irrespective of the reason.
Because it is a poor prognostic indicator and measure of 
quality of life and cost, rehospitalization is usually included ei-
Table 3. Clinical outcomes in groups according to change in sNa levels at discharge
 Corrected hyponatremia Persistent hyponatremia Hospital-acquired hyponatremia Normonatremia P 
 n=61 n=59 n=77 n=219
1-year mortality 6 (11.3) 10 (20) 3 (4.3) 5 (2.5) <.001
Rehospitalization 23 (37.7) 29 (49.2) 30 (39%) 64 (29.2) 0.028
Values are given as numbers (%). The chi-square test was used
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Figure 2. Kaplan–Meier survival curves for patients stratified into four 
groups according to changes in sNa levels from baseline to discharge
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ther alone or belonging to a composite clinical end point in stud-
ies examining various aspects of HF. We found that patients with 
low sNa levels experienced higher rehospitalization rates than 
normonatremic patients in our cohort. In other studies, when 
examined as a composite end-point usually with mortality, it 
was observed that rehospitalization incidence was increased in 
hyponatremic patients (2, 4, 12, 13). However, this relation does 
not always exist when it is examined as an individual end-point. 
In the Optimize HF registry, the rehospitalization rate was high 
in hyponatremics but was independent of sNa levels. Likewise, 
RICA investigators reported that after Cox regression adjust-
ment, it was the co-morbidities rather than hyponatremia that 
affected readmission rates (16). On the other hand, in ambula-
tory patients with HFrEF, hyponatremia was found to be an inde-
pendent predictor of hospitalization (10).
In most studies, hyponatremia was found to be an indepen-
dent predictor of mortality in HF patients (2, 5, 12). In our cohort, 
there was a strong and independent association between hypo-
natremia and mortality. However, the causality of this associa-
tion is still questioned. Chawla et al. (20) demonstrated that the 
nature of the underlying illness, rather than the severity of hypo-
natremia, best explain mortality associated with hyponatremia. 
More recently, regarding rehospitalization, RICA investigators 
stated that comorbidities not hyponatremia were independent 
predictors of mortality (16). We accept that there might be an 
interaction between hyponatremia, comorbidities, and mortality, 
but because the current available data overwhelmingly indicates 
an independent association, this study supports that hyponatre-
mia increases mortality rates in HF patients.
A more controversial issue related to sNa level and clinical 
outcomes in HF is how changes in sNa levels during the course 
of hospitalization affect clinical outcomes. HF patients with per-
sistent hyponatremia, i.e., present both on admission and at dis-
charge, have the highest mortality and rehospitalization rates 
compared with all-time normonatremics, and these differences 
were significant in this study. This is concordant with previously 
reported studies focusing on the same issue (2, 3, 21). Therefore, 
it seems reasonable to improve the clinical outcomes by correct-
ing hyponatremia. There is a scarcity of studies addressing this 
issue with many contradictory results. In a report from OPTIME-
CHF, study patients with corrected hyponatremia (>135 mEq/L) at 
discharge had a lower death rate compared with patients with 
persistent hyponatremia; however, it was not significant (2). In 
a study that included only hyponatremic patients, Madan et al. 
(21) reported that increase in sNA levels significantly decreased 
mortality rates. A substudy of ESCAPE Trial examining the prog-
nostic value of persistent hyponatremia also looked for the effect 
of correcting this electrolyte abnormality on clinical outcomes. 
Compared with persistent hyponatremics, corrected hypona-
tremia improved neither mortality nor rehospitalization rates (3). 
However, when mortality and rehospitalization were considered 
as a composite end point, correcting low sNa levels significantly 
decreased adverse outcomes. A study from Korea showed that 
compared with the normonatremics, correcting hyponatremia 
does not improve clinical outcomes (22). Although they did not 
report any comparison between persistent and corrected hypo-
natremia, in their article, they depicted a better Kaplan–Meier 
survival curve for corrected hyponatremia. In our study, correc-
tion in sNa during the course of hospitalization tends to be asso-
ciated with better outcomes than the persistent hyponatremia; 
however, this difference was not statistically significant. It can 
be briefly said that very limited data related with the correction 
of low sNa levels, and its clinical consequences is not conclu-
sive. None of the studies reported measures taken to increase 
sNa levels. This uncertainty makes the issue even more complex. 
Therefore, it is obvious that in order to resolve this issue, a well-
designed prospective randomized controlled trial is needed.
Study limitations
The present study inherits all the limitations of retrospective 
studies. Data were dependent on the accuracy of documenta-
tion and abstraction by centers that participated. We did not 
collect information regarding the dose of diuretics and nonphar-
macological treatments, such as ICD and CRT. Because of the 
observational nature of the study, we are unable to provide in-
sights into the mechanisms underlying the association between 
hyponatremia, mortality, and rehospitalization. In additiona, our 
study did not specifically address the importance of correcting 
electrolyte disorders. Despite covariate adjustment, other mea-
sured and unmeasured factors might have influenced outcomes. 
Although we adjusted for multiple covariates during the index 
admission, we did not adjust for changes in these parameters 
during the follow-up.
Conclusion
Hyponatremia is common in Turkish patients hospitalized for 
worsening HF. Low sNa levels in this population were an inde-
pendent and strong risk factor for increased mortality and re-
hospitalization. While patients with persistent hyponatremia dur-
ing the course of their hospitalization had the worst outcomes, it 
remains unknown if correcting this electrolyte abnormality might 
increase event-free survival in HF patients. Prospective confir-
mation of our findings in a larger population is needed.
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